Another drug that was recently described with positive results against ERBB2-positive GC is lapatinib, an intracellular tyrosine kinase inhibitor of EGFR and ERBB2 that acts by blocking autophosphorylation and downstream signaling. Here, EGFR is linked to gastric cancer.